Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies - PubMed (original) (raw)
Review
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al. Lancet Diabetes Endocrinol. 2019 Apr.
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In some patients with NAFLD, isolated steatosis can progress to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and hepatocellular carcinoma. Furthermore, NAFLD is believed to be involved in the pathogenesis of common disorders such as type 2 diabetes and cardiovascular disease. In this Review, we highlight novel concepts related to diagnosis, risk prediction, and treatment of NAFLD. First, because NAFLD is a heterogeneous disease, the advanced stages of which seem to be strongly affected by comorbidities such as insulin resistance and type 2 diabetes, early use of reliable, non-invasive diagnostic tools is needed, particularly in patients with insulin resistance or diabetes, to allow the identification of patients at different disease stages. Second, although the strongest genetic risk alleles for NAFLD (ie, the 148Met allele in PNPLA3 and the 167Lys allele in TM6SF2) are associated with increased liver fat content and progression to NASH and cirrhosis, these alleles are also unexpectedly associated with an apparent protection from cardiovascular disease. If consistent across diverse populations, this discordance in NAFLD-related risk prediction between hepatic and extrahepatic disease might need to be accounted for in the management of NAFLD. Third, drug treatments assessed in NAFLD seem to differ with respect to cardiometabolic and antifibrotic efficacy, suggesting the need to better identify and tailor the most appropriate treatment approach, or to use a combination of approaches. These emerging concepts could contribute to the development of a multidisciplinary approach for endocrinologists and hepatologists working together in the management of NAFLD.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
- Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Kanda T, et al. Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525. Int J Mol Sci. 2020. PMID: 32102237 Free PMC article. Review. - Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M. Traussnigg S, et al. Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Dig Dis. 2015. PMID: 26159280 Review. - Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Athyros VG, et al. Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313. Curr Vasc Pharmacol. 2020. PMID: 30961499 Review. - Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G. Firneisz G. World J Gastroenterol. 2014 Jul 21;20(27):9072-89. doi: 10.3748/wjg.v20.i27.9072. World J Gastroenterol. 2014. PMID: 25083080 Free PMC article. Review. - Non-alcoholic fatty liver disease and risk of type 2 diabetes.
Lallukka S, Yki-Järvinen H. Lallukka S, et al. Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95. doi: 10.1016/j.beem.2016.06.006. Epub 2016 Jun 23. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 27432073 Review.
Cited by
- Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease.
Ábel T, Benczúr B, Csobod ÉC. Ábel T, et al. Front Med (Lausanne). 2024 Sep 23;11:1458025. doi: 10.3389/fmed.2024.1458025. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39376658 Free PMC article. Review. - Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.
Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Zheng H, et al. Cardiovasc Diabetol. 2024 Sep 28;23(1):346. doi: 10.1186/s12933-024-02434-5. Cardiovasc Diabetol. 2024. PMID: 39342178 Free PMC article. Review. - Lipoprotein(a) level predicts the development of nonalcoholic fatty liver disease in Korean adults: A retrospective longitudinal study.
Nam JS, Park K, Baik SJ, Park JS. Nam JS, et al. Medicine (Baltimore). 2024 May 31;103(22):e38340. doi: 10.1097/MD.0000000000038340. Medicine (Baltimore). 2024. PMID: 39259121 Free PMC article. - Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.
Lu Q, Zhu R, Zhou L, Zhang R, Li Z, Xu P, Wang Z, Wu G, Ren J, Jiao D, Song Y, Li J, Wang W, Liang R, Ma X, Sun Y. Lu Q, et al. mSystems. 2024 Sep 17;9(9):e0079424. doi: 10.1128/msystems.00794-24. Epub 2024 Aug 21. mSystems. 2024. PMID: 39166878 Free PMC article. - Dual-layer spectral-detector CT for detecting liver steatosis by using proton density fat fraction as reference.
Wang M, Chen H, Ma Y, Bai R, Gao S, Yang L, Guo W, Zhang C, Kang C, Lan Y, Sun Y, Zhang Y, Xiao X, Hou Y. Wang M, et al. Insights Imaging. 2024 Aug 15;15(1):210. doi: 10.1186/s13244-024-01716-6. Insights Imaging. 2024. PMID: 39145877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical